Marimekko Corporation
Release of Marimekko's Interim Report, 1 January–31 March 2025
Release of Marimekko's Interim Report, 1 January–31 March 2025
Marimekko Corporation, Press release 7 May 2025 at 11.00 a.m. EEST
Release of Marimekko's Interim Report, 1 January–31 March 2025
Marimekko Corporation’s Interim Report 1 January–31 March 2025 will be published on Wednesday 14 May 2025 at 8.00 a.m. EEST. The report and related materials will be available on the company’s website at https://company.marimekko.com/investors/ after the publication.
A media and investor conference will be held in English on 14 May 2025 at 2.00 p.m. EEST. A live webcast of the conference can be followed at https://marimekko.videosync.fi/q1-2025, and a recording of the webcast will be available at the same address later. Questions can be asked during the live webcast in writing.
Additional information:
Anna Tuominen, Marimekko Communications
Tel. +358 40 584 6944
anna.tuominen@marimekko.com
DISTRIBUTION:
Key media
Marimekko is a Finnish lifestyle design company renowned for its original prints and colors. The company’s product portfolio includes high-quality clothing, bags and accessories as well as home décor items ranging from textiles to tableware. When Marimekko was founded in 1951, its unparalleled printed fabrics gave it a strong and unique identity. In 2024, the company's net sales totaled EUR 183 million and comparable operating profit margin was 17.5 percent. Globally, there are roughly 170 Marimekko stores, and online store serves customers in 39 countries. The key markets are Northern Europe, the Asia-Pacific region and North America. The Group employs about 480 people. The company’s share is quoted on Nasdaq Helsinki Ltd. www.marimekko.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Akero Therapeutics Inc.9.5.2025 13:41:09 CEST | Press release
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
Strategic Partners A/S9.5.2025 13:40:35 CEST | Pressemeddelelse
Aktietilbagekøbsprogram fra maj - august 2025
Novo Nordisk A/S9.5.2025 13:22:39 CEST | Press release
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Akero Therapeutics Inc.9.5.2025 13:11:31 CEST | Press release
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Municipality Finance Plc9.5.2025 12:00:00 CEST | Press release
Municipality Finance issues EUR 40 million notes under its MTN programme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom